The legal library gives you easy access to the FTC’s case information and other official legal, policy, and guidance documents.
20170681: Targa Resources Corp.; Kayne Anderson Energy Fund VI, L.P.
20170682: Targa Resources Corp.; Denham Commodity Partners Fund VI LP
20170742: The Resolute Fund III, L.P.; DB Parent, Inc.
20170744: Precision Parent, LLC; PGPC-Signicast-2 LLC
20170745: Hexagon AB; STG III, L.P.
20170750: Keysight Technologies, Inc.; Ixia
20170754: Golden Gate Capital Opportunity Fund, L.P.; GTCR Fund XI/B LP
Response to Requester
FleetCor consumer complaints (September 20 2016 to February 22 2017)
Comdata consumer complaints (September 20 2016 to February 22 2017)
Fleet Card Fuelman consumer complaints (September 20 2016 to February 22 2017)
20170660: Educational Testing Service; Questar Assesment, Inc.
20170708: Ascential plc; Michael E. Kassan
20170728: Ingenic Semiconductor Co., Ltd.; Beijing OmniVision Technologies, Co. Ltd.
20170739: RPC Group Plc; Letica Corporation
20170753: Hainan Cihang Foundation; SkyBridge Capital II, LLC
C.H. Boehringer Sohn, In the Matter of
Boehringer Ingelheim agreed to divest five types of animal health products in the United States in order to settle FTC charges that its proposed asset swap with Sanofi would likely be anticompetitive. Under the proposed swap, Boehringer Ingelheim acquired Sanofi’s animal care subsidiary, Merial, valued at $13.53 billion, and Sanofi obtained Boehringer Ingelheim’s consumer health care business unit, valued at $7.98 billion, as well as cash compensation of $5.54 billion. The FTC’s complaint alleges that without the divestitures the proposed asset swap would harm competition in the U.S. markets for various vaccines for companion animals (pets) and certain parasite control products for cattle and sheep. The proposed consent order preserves competition by requiring Boehringer Ingelheim to divest the companion animal vaccines to Eli Lilly and the company’s Elanco Animal Health division, and the parasite control products to Bayer AG.